All News

To help combat the nation’s opioid epidemic, FDA is promoting a more tailored approach to developing and testing effective analgesics, with the aim of bringing less addictive pain treatments to market more quickly.

Faced with looming uncertainties triggered by the upcoming Brexit, the United Kingdom’s life sciences sector, which constitutes one of the last big remaining bastions of British industry, is not about to rest on its laurels.

Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.

The opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. George P. Sillup and Stephen J. Porth report.

The importance of digital engagement in the biopharma industry continues to be influenced by advancements in the technology industry as well as changes in patient needs.

Using AI to revolutionize research inefficiency. 

European drug innovators ready their defense as the Commission mulls manufacturing waiver for generic competitors.

Click the title above to open the Pharmaceutical Executive August 2018 issue in an interactive PDF format.

The importance of early development strategy and planning for biologic patent term extension.

Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.

Reputation Institute study finds that the reputation of pharma companies is in decline and might get worse before it gets better.

My first gathering of Pharm Exec's Editorial Advisory Board was both an honor and a learning experience-about us, the industry, and maintaining our mission to the our readers.